Brief: Ipsen Says U.S. FDA Grants Ipsen’s IPN60340 Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia

Ipsen SA

13/01/2026 17:42

Jan 13 (Reuters) - Ipsen SA IPN.PA:

U.S. FDA GRANTS IPSEN’S IPN60340 (ICT01) BREAKTHROUGH THERAPY DESIGNATION IN FIRST LINE UNFIT ACUTE MYELOID LEUKEMIA

IPSEN SA: TO DISCUSS DESIGN OF PHASE II/III DEVELOPMENT PLANS WITH FDA FOR IPN60340 IN H1 2026

Source text: ID:nGNX26fbMt

Further company coverage: IPN.PA

 (((( Reuters.Briefs@thomsonreuters.com ;));))